The role of orexin hormone in sera of patients with metabolic syndrome of Kerbala province: Iraq

Abstract

Objectives MetS is a disorder consisting of various abnormalities such as dyslipidemia, obesity, hypertension and hyperglycemia. Over the past two decades, the prevalence of MetS has greatly increased, then increasing the risk of heart disease, stroke and diabetes, and it has become a global health problem. Orexin is a neuropeptide secreted by a group of hypothalamic neurons. Orexin neurons in the hypothalamus have widespread projections throughout the brain and peripheral structures.
Methods This study was conducted at Al-Hussein Teaching Hospital and Al-Zahraa Teaching Hospital of Al-Hussein Medical City, Kerbala Health Directorate, Kerbala, Iraq from June 2015 to March 2016. The 124 samples (52 males and 72 females) were randomly selected from MetS patients attending the abdominal consultation unit. The results obtained were compared between diabetic patients with non-diabetic group. The age range for all samples used in this study was between (35 and 65) years. Patients with MetS were divided into various groups depending upon the BMI and blood pressure. Body mass index, age, blood pressure, and fasting glucose were determined beside to the levels of the orexin hormone.
Results The results show that significant decrease (P < 0.05) in serum levels of orexin hormone in MetS with type 2 diabetic patients as compared with MetS without type 2 diabetes mellitus.
Conclusion The data observed indicate that the level of orexin hormone in MetS with and without T2DM was changed according to gender, BMI, age, duration of disease and blood pressure.